2023 Impact Factor
2023 Impact Factor
Studies evaluating 20-item Toronto Alexithymia Scale (TAS-20) scores in irritable bowel syndrome (IBS) patients vs controls. The figure shows an overall mean difference between the TAS-20 scores in IBS patients vs healthy controls of 8.063 (95% CI, 2.554-13.572). Hence, TAS-20 scores are significantly higher in IBS patients compared to healthy controls. The heterogeneity is significant with an I2 of 95.88% and a P-value lower than 0.001.
The neural pathway controlling the inhibitory and excitatory relationship between pharyngeal and esophageal phases of swallowing. This figure is a combination of Figures 3 and 6 in which the excitatory and inhibitory effects can be observed in one figure. While the normal swallow process activates an excitatory as well as inhibitory process, the brainstem nuclei control the timing such that the inhibitory process occurs at the very beginning of primary peristalsis and the excitatory process is delayed by a few seconds. NTSa, one portion of the nucleus; NTSb, another portion of the nucleus tractus solitarius; SLN, super laryngeal nerve; 1°P, primary peristalsis; CPGp, pharyngeal phase central pattern generator; CPGe, esophageal phase central pattern generator; GPN, glossopharyngeal nerve; PEIR, pharyngo-esophageal inhibitory reflex; RNL, recurrent laryngeal nerve; EPSR, esophago-pharyngeal swallow reflex; 2°P, secondary peristalsis; McST, mucosal slowly-adapting tension receptors.
High-resolution manometry result of 61-year-old whose diagnosis was changed by rapid drink challenge.
Comparison between primary care clinicians and gastroenterologists in university hospitals on the following questions of prescription patterns. (A) “What is the initial period of neuromodulator use in patients with functional gastrointestinal disorders (FGIDs)?”, (B) “How long are neuromodulators used if they are effective for patients with FGIDs?”, (C) “Which neuromodulator do you use for patients with FGIDs?” (*P < 0.05), (D) Comparison of the reasons for not prescribing neuromodulators (participants who indicated they did not use neuromodulators). TCA, tricyclic antidepressant; SSRI, selective serotonin-reuptake inhibitor; SNRI, serotonin–noradrenalin-reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; SSRE, selective serotonin-reuptake enhancer.
J Neurogastroenterol Motil 2024; 30(4): 381~519 
Total PDF
.jpg)
